As of February 2022, the latest COVID-19 vaccine by Sanofi/GlaxoSmithKline showed a 77 percent efficacy against the Delta variant of the coronavirus. This statistic illustrates the comparison of select COVID-19 vaccines worldwide, by their efficacy against the Delta variant.

As of April 26, 2023, roughly 367 million Pfizer-BioNTech COVID-19 vaccine doses had been administered in the United States. This statistic shows the number of COVID-19 vaccinations administered in the United States as of April 26, 2023, by manufacturer.

The graph depicts Pfizer's top 10 products based on revenue in 2024. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2024, Pfizer's top product was Eliquis. COVID-19 vaccine Comirnaty, on the other hand, showed another dramatic decline in sales from **** billion U.S. dollars in 2023 to *** billion dollars. Pfizer's top productsPfizer is a pharmaceutical corporation headquartered in New York City, United States. It was founded in **** by Charles Pfizer and Charles Erhart in Brooklyn, New York, where they produced an antiparasitic called santonin. Today, Pfizer produces pharmaceutical products for a wide range of medical sectors that include but are not limited to immunology, cardiology, and neurology. In 2024, Pfizer generated a total revenue of **** billion U.S. dollars worldwide, with oncology products accumulating some **** billion U.S. dollars.Some of Pfizer’s well-known products - although with expired patent protection - include Lyrica and Lipitor, which generated around *** and * billion U.S. dollars in revenue, respectively, in 2019. Pregabalin, marketed as Lyrica, is an anticonvulsant drug used to treat disorders such as epilepsy, diabetic peripheral neuropathy, and fibromyalgia. Lipitor, one of Pfizer’s more well-known products, generated revenues of **** billion U.S. dollars in 2006, however, after Pfizer’s patent on Lipitor expired in 2011, revenue has fallen to under * billion U.S. dollars. Currently, generic forms of atorvastatin (Lipitor) are available. Lipitor is a statin that is used to lower blood cholesterol and to prevent cardiovascular diseases.

NOTE: As of 2/16/2023, this table is no longer being updated. For data on COVID-19 Updated (Bivalent) Booster Coverage by Age go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Age-/j2me-7k56. For information on COVID-19 vaccination primary series coverage for people less than 5 years go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccination-Primary-Series-Coverage-Age-L/su9q-qn6e Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages for state- and county-level tables (except coverage by CT SVI priority zip code). 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated, and addition dose 1 by age group. Age is based on age at the time of administration of the first dose. All data in this report are preliminary; data for previous dates will be updated as new reports are received, and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully

Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2024, the company's total revenue stood at **** billion U.S. dollars. Pfizer’s global positioning Pfizer’s products are available in many countries worldwide and as of 2024, the company had more than *** research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few. Pfizer’s top products In 2024, products from the Prevnar family were among Pfizer's top products based on revenue. However, Pfizer has several other drugs that are also well-known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline due to patent loss, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Financial overview and grant giving statistics of Pfizer, Inc.

Pfizer is a multinational pharmaceutical company that is headquartered in New York City, New York. Pfizer’s expenditures on research and development (R&D) have been variable in recent history. In 2024, Pfizer spent some **** billion U.S. dollars on R&D efforts. Pfizer’s company profile Pfizer is one of the world’s largest pharmaceutical companies. The company has pharmaceuticals in a number of therapeutic areas, including oncology, endocrinology, cardiology, and neurology. The Prevnar family is one of Pfizer’s top revenue-generating drugs. Prevnar is a vaccine used to prevent pneumococcal pneumonia. The company has undergone several mergers and acquisitions in recent history. In 1999, Pfizer and Warner-Lambert joined, forming one of the most valuable pharmaceutical mergers of all time. Pharmaceutical research and development Pharmaceutical R&D is crucial for finding and creating new drug compounds and agents that have the potential to save lives (or improve medical symptoms). Pharmaceutical R&D in the U.S. has become a booming industry and spending is increasing year-over-year. The number of federally registered clinical trials in the U.S. has been increasing significantly recently as well. One area of health that has been significantly impacted by R&D investment is oncology.

Financial overview and grant giving statistics of Pfizer Patient Assistance Foundation Inc

NOTE: As of 2/16/2023, This page is not being updated, for data on COVID-19 Updated (Bivalent) Booster Coverage go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Town/bqd5-4jgh. Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages at the county level. 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated and had additional dose 1 by county of residence. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. A person who has received at least one dose of any COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have initiated vaccination. Percentages are calculated using 2019 census data (https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Annual-Town-and-County-Population-for-Connecticut). A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose may be over-estimated and the percent fully and additional dose 1 vaccinated may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. County of residence is determined based on the town of residence. Town of residence is verified by geocoding the reported address and then mapping it to a town using municipal boundaries. If an address cannot be geocoded, the reported town is used, if available. Out-of-state residents vaccinated by CT providers excluded from this table. People for whom an address is not currently available are shown in this table as “Address pending validation”. Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction.

Moderna stock dropped nearly 5% following a competitive vaccine update from Pfizer-BioNTech and its own distant 2028 profitability target, contributing to a 42.9% YTD decline.

Financial overview and grant giving statistics of Pfizer Retiree Medical Plan

The statistic shows the number of employees at pharmaceutical company Pfizer from 2006 to 2024. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2024, Pfizer employed approximately ****** persons around the world. The highest number of employees at Pfizer was reported in 2009, with almost *** thousand employed persons. Pfizer company factsPfizer is a pharmaceutical corporation with its headquarters in New York City, United States. It was founded in **** by Charles Pfizer and Charles Erhart in Brooklyn, New York. Their first product was an antiparasitic called santonin. Currently, Pfizer produces pharmaceutical products for a wide range of medical sectors such as immunology, cardiology, and neurology. Global revenue at Pfizer reached a record-high of over 100 billion U.S. dollars in 2022. Pfizer is active in many countries around the globe. Its research and development activities are focused on the discovery of small molecules as well as large-molecules (biologics), and the development of vaccines. The total number of employees working for Pfizer has decreased from ******* in 2009 to below ****** in 2021. After a merger with Wyeth in 2009, Pfizer cut over ****** employees. Pfizer has been named one of Canada’s top 100 employers by Maclean’s magazine in 2007, but has also been subject to controversy in employment in other countries, like in the United States.

Pfizer, once thriving on pandemic sales, now tackles revenue challenges with a strategic focus on oncology and vaccines, aiming for long-term growth.

The statistic shows the total assets of pharmaceutical company Pfizer from 2006 to 2024. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2024, Pfizer's total assets came to some 213 billion U.S. dollars.

This statistic depicts revenues of pharmaceutical company Pfizer from 2022 to 2024, by segment. The Primary Care segment, which includes the COVID-19 vaccine Comirnaty, is the company's ********* segment. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. Due to the Upjohn spin-off during 2020 and the Consumer Healthcare business merger with GSK's consumer health segment to form a new joint venture in 2019, only the Biopharma segment remained.

Pfizer forecasts 2025 sales between $61B-$64B, meeting Wall Street expectations, amid strategic moves like cost cuts and leadership in R&D.

Discover the implications of a German court ruling against Pfizer-BioNTech in a vaccine patent case favoring Moderna.

The FDA's pending decision on Novavax's COVID-19 vaccine approval raises concerns in the pharmaceutical sector, impacting stocks and future payouts.

Sales from the United States contributed more than 38 billion U.S. dollars towards Pfizer's total revenue of around 63.6 billion U.S. dollars in 2023. Pfizer sees strong growth in emerging markets Pfizer’s total revenue is divided into four geographic areas: the United States, Developed Markets, and Emerging Markets. China is one of the company’s largest single markets behind the United States, which contributed 60 percent of Pfizer’s total revenue. Pfizer continues to support investment in emerging markets, but the vulnerable nature of these countries means strategies come with an element of risk due to unforeseen financial or political events, for example. The power of product patents Managing the expiration of key patents is one of the greatest challenges facing Pfizer because competition from generic versions can make a big difference to company revenues. Many of Pfizer’s leading products enjoy the security of market exclusivity, but less expensive generic versions are free to enter the market when these property rights end. In 2019, Pfizer anticipated a fall in sales revenue from China due to significant competition from generic versions.